OIG OKs Drug Maker to Cover Patients’ Round-Trip Expenses for Cell-Removal Needed in Personalized Therapy
- June 03, 2022
The Department of Health and Human Services Office of Inspector General (OIG) in a modified advisory opinion posted June 1 said a drug manufacturer could provide additional financial assistance for travel expenses to patients prescribed its personalized therapy as part of a previously approved arrangement without risking sanctions.
ARTICLE TAGS
You must be logged in to access this content.